Investopedia: Abbott Labs Making Progress On Margins, Now It Needs More Growth

Since making the split from AbbVie (Nasdaq:ABBV), Abbott Labs (NYSE:ABT) has had something of a mixed debut. The stock has not only lagged AbbVie to a meaningful degree this year, but also other med-tech stocks like Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ). While some of this can be tied to concerns about the infant nutrition business, the fact remains that the new Abbott isn't as high-growth or high-margin as some investors want to believe, and management has their work cut out to improve performance. I do like the company's recent M&A moves to bulk up the device business, but this doesn't look like a particularly cheap stock today.

Please follow this link to continue:
http://www.investopedia.com/stock-analysis/071713/abbott-labs-making-progress-margins-now-it-needs-more-growth-abt-mjn-mdt-jnj.aspx